Compare Mesoblast Limited (MESO) vs Oklo Inc (OKLO) Price & Performance

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.

OKLO trades at $36.82, down 4.49% with bearish technical signals. The company shows no revenue in 2025 and negative net income of -$105.66M, with profitability metrics deeply negative. Recent earnings have missed expectations in two of the last three quarters. However, analyst sentiment remains strong with 71% buy ratings and a $78.63 consensus price target, reflecting optimism about the nuclear energy opportunity.

The outlook balances high growth potential in the nuclear sector against significant execution risks. While the $10 trillion nuclear opportunity and partnerships with hyperscalers provide upside, OKLO faces challenges including negative cash flow from operations, substantial dilution from recent stock sales, and intense competition in the small modular reactor market.